AKT1 and acute myeloid leukemia: FLT3-ITD mutation is the most frequently identified genetic event in AML that results in the activation of several signaling pathways, including Janus activated kinase/signal transducer and activator of transcription (JAK/STAT) and Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathways [4,5].